April 2012

To Shareholders,

As we outlined in our inaugural Investor Bulletin last month, we are committed to providing you with consistent and transparent information to help you better understand how we are building this company.

In April, staff and management at CRH Medical participated in several initiatives that will support the growth of our business.

As you may know, gastroenterologists (GIs) are the life blood of our business; they are our primary customers and their decision as to whether or not to incorporate hemorrhoid treatment using the CRH O’Regan System into their practice has huge ramifications on our financial results.

That said, this past month we launched two marketing videos to encourage GIs in our database to either increase their usage of the System, or to introduce this effective treatment to their patients for the first time.  The single use O’Regan System is clinically proven to treat all grades of hemorrhoids and is quickly becoming the gold standard for gastroenterologists throughout the United States.

Below is a link to a video that approximately 1,100 GIs and surgeons (who have been trained on the technology) received directly by email.  This video focuses on the support resources offered by CRH.


The next link, emailed to about 6,000 physicians, takes viewers to a video that we developed to effectively introduce the O’Regan System to gastroenterologists who are still learning about the product.


We’re confident that these marketing initiatives will augment our ongoing efforts to increase our already growing O’Regan System sales in the U.S.

For those who have not yet seen our first quarter press release , which includes revenue results, the link below will take you directly to it.


With regards to our ongoing efforts to market the O’Regan System, at the end of March, we presented details about the System at a prominent, annual gastroenterology conference in Knoxville, Tennessee. Top gastroenterologists from the United States attending the 2012 GI Roundtable learned how our patented technology can increase their revenues while providing their patients with a safe and effective hemorrhoid treatment.

By attending the conference, we generated a number of leads for new, prospective customers. We were also able to spend time with many of our current customers who provided feedback about the positive impact the CRH O’Regan System is having on their practices and their patients.

While we recognize that it’s crucial to stay visible with our customers, we also feel it’s important to raise our profile with the investment community.

To that end, CRH Medical’s CEO, Edward Wright, and the Company’s Chairman of the Board, Tony Holler, will be in New York in early May to introduce the story to the investment community there.

We’ll also be busy in Toronto towards the end May at BioFinance, which is Canada’s largest life sciences investment conference.

We look forward to sharing May’s edition of the CRH Investor Bulletin with you next month, and as always, we appreciate your interest and support.



Adam Peeler, Media and Investor Relations
TMX Equicom
416.815.0700 x 225

We're a stable, profitable company respected by both patients and physicians. Learn more »